why Adaptive Biotechnologies Corporation [ADPT] is a Good Choice for Investors After New Price Target of $51.67

Adaptive Biotechnologies Corporation [NASDAQ: ADPT] price surged by 2.05 percent to reach at $0.81. The company report on August 4, 2020 that Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2.

Tailored for vaccine developers to accurately and reproducibly measure and track COVID-19 specific T-cell response in clinical trials.

Powered by T-cell immune response data from over 1,000 COVID-19 patients from ImmuneCODE, the largest public database mapping T-cell receptors (TCRs) to SARS-CoV-2.

A sum of 1054173 shares traded at recent session while its average daily volume was at 1.17M shares. Adaptive Biotechnologies Corporation shares reached a high of $40.59 and dropped to a low of $38.87 until finishing in the latest session at $40.24.

The one-year ADPT stock forecast points to a potential upside of 22.12. The average equity rating for ADPT stock is currently 1.50, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Adaptive Biotechnologies Corporation [ADPT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADPT shares is $51.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADPT stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Goldman have made an estimate for Adaptive Biotechnologies Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 03, 2020. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on July 23, 2019, representing the official price target for Adaptive Biotechnologies Corporation stock.

The Average True Range (ATR) for Adaptive Biotechnologies Corporation is set at 1.97, with the Price to Sales ratio for ADPT stock in the period of the last 12 months amounting to 58.75. The Price to Book ratio for the last quarter was 9.19, with the Price to Cash per share for the same quarter was set at 4.08.

ADPT Stock Performance Analysis:

Adaptive Biotechnologies Corporation [ADPT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.45. With this latest performance, ADPT shares dropped by -14.33% in over the last four-week period, additionally plugging by 36.92% over the last 6 months – not to mention a rise of 14.58% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADPT stock in for the last two-week period is set at 49.90, with the RSI for the last a single of trading hit 52.52, and the three-weeks RSI is set at 48.82 for Adaptive Biotechnologies Corporation [ADPT]. The present Moving Average for the last 50 days of trading for this stock 42.23, while it was recorded at 38.67 for the last single week of trading, and 32.39 for the last 200 days.

Insight into Adaptive Biotechnologies Corporation Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Adaptive Biotechnologies Corporation [ADPT] shares currently have an operating margin of -92.15 and a Gross Margin at +65.86. Adaptive Biotechnologies Corporation’s Net Margin is presently recorded at -81.78.

Return on Total Capital for ADPT is now -17.22, given the latest momentum, and Return on Invested Capital for the company is -15.28. Return on Equity for this stock declined to -44.46, with Return on Assets sitting at -11.18. When it comes to the capital structure of this company, Adaptive Biotechnologies Corporation [ADPT] has a Total Debt to Total Equity ratio set at 6.41. Additionally, ADPT Total Debt to Total Capital is recorded at 6.02, with Total Debt to Total Assets ending up at 4.01. Long-Term Debt to Equity for the company is recorded at 6.41, with the Long-Term Debt to Total Capital now at 6.02.

Reflecting on the efficiency of the workforce at the company, Adaptive Biotechnologies Corporation [ADPT] managed to generate an average of -$153,576 per employee. Receivables Turnover for the company is 9.73 with a Total Asset Turnover recorded at a value of 0.14.Adaptive Biotechnologies Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.40 and a Current Ratio set at 7.50.


With the latest financial reports released by the company, Adaptive Biotechnologies Corporation posted -1.23/share EPS, while the average EPS was predicted by analysts to be reported at -0.14/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -778.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADPT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adaptive Biotechnologies Corporation go to 9.00%.

Adaptive Biotechnologies Corporation [ADPT] Insider Position Details

There are presently around $3,821 million, or 74.00% of ADPT stock, in the hands of institutional investors. The top three institutional holders of ADPT stocks are: VIKING GLOBAL INVESTORS LP with ownership of 33,493,708, which is approximately -12.792% of the company’s market cap and around 1.40% of the total institutional ownership; MATRIX CAPITAL MANAGEMENT COMPANY, LP, holding 15,115,090 shares of the stock with an approximate value of $608.23 million in ADPT stocks shares; and BLACKROCK INC., currently with $199.62 million in ADPT stock with ownership of nearly 57.06% of the company’s market capitalization.

Positions in Adaptive Biotechnologies Corporation stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 120 institutional holders increased their position in Adaptive Biotechnologies Corporation [NASDAQ:ADPT] by around 21,730,892 shares. Additionally, 49 investors decreased positions by around 12,117,043 shares, while 13 investors held positions by with 61,105,690 shares. The mentioned changes placed institutional holdings at 94,953,625 shares, according to the latest SEC report filing. ADPT stock had 50 new institutional investments in for a total of 3,560,193 shares, while 20 institutional investors sold positions of 1,766,070 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam